Geron (GERN) Restructuring Costs (2012 - 2026)

Geron's (GERN) quarterly Restructuring Costs came in at -$394000.0 in Q1 2026, down 860.98% quarter-over-quarter from -$41000.0 in Q3 2015.

Geron (GERN) Restructuring Costs (2012 - 2026) Analysis & Trends

Geron has disclosed Restructuring Costs across 4 years of filings, most recently posting -$394000.0 for Q1 2026.

Restructuring Costs for Q1 2026 came in at -$394000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$435000.0 (down 148.33% YoY), and the FY2025 annual result was $17.0 million, changed N/A from the prior year.
Restructuring Costs came in at -$394000.0 for Q1 2026 at Geron, down from -$41000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of -$394000.0 in Q1 2026 to a low of -$394000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Geron	753,046.88	753,046.88	-

Download Data